Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
暂无分享,去创建一个
Mitch Dowsett | Marion Procter | Brian Leyland-Jones | Urania Dafni | M. Dowsett | R. Gelber | W. McCaskill-Stevens | U. Dafni | B. Leyland-Jones | G. Viale | M. Piccart-Gebhart | M. Procter | M. Abramovitz | E. de Azambuja | S. Dolci | Giuseppe Viale | Martine Piccart-Gebhart | Richard D Gelber | Worta McCaskill-Stevens | Evandro de Azambuja | O. Stoss | Stella Dolci | Mark Abramovitz | Josef Rueschoff | Bruce Jordan | Oliver Stoss | J. Rueschoff | Bruce Jordan
[1] Jorma Isola,et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.
[2] E. Perez,et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer , 2007 .
[3] Jorma Isola,et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Paik,et al. HER2 status and benefit from adjuvant trastuzumab in breast cancer. , 2008, The New England journal of medicine.
[5] I. Ellis,et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[7] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[8] R. Gelber,et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Alan Mackay,et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines , 2008, Laboratory Investigation.
[10] John R. Mackey,et al. Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .
[11] D. Larsimont,et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] T. Grogan,et al. The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic mRNA In Situ Hybridization Study , 2005, The American journal of surgical pathology.
[13] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[14] E. Perez,et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Paik,et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 , 2007 .
[16] David Cameron,et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.
[17] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[18] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[19] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[20] T. Yamamoto,et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.
[21] Patrick Neven,et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Dowsett,et al. Standardization of HER2 testing: results of an international proficiency-testing ring study , 2007, Modern Pathology.
[23] M. Greenwood. A Report on the Natural Duration of Cancer. , 1926 .
[24] Gottfried Konecny,et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.